Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Feldman Discusses Using Doxil for CTCL

December 19th 2011

Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL

What is the best way to administer bendamustine, since some clinicians classify it as an irritant and others classify it as a vesicant?

December 16th 2011

Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.

Day in the Life of an Oncology/Hematology Fellowship Program Director

December 15th 2011

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

What Oncology and Hematology Fellows Can Do to Reduce Their Loan Debt

December 15th 2011

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Dr. Mato on the Benefits of the JTCC Retrospective Trial

December 13th 2011

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

December 13th 2011

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

December 12th 2011

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

December 12th 2011

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

December 12th 2011

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

December 12th 2011

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

December 11th 2011

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

December 11th 2011

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. Kochenderfer Discusses the B-cell Antigen CD19

December 10th 2011

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Feldman Discusses the Difficulties of Rare Lymphomas

December 10th 2011

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Channeling His Creativity Into Oncology: A "Renaissance Man" Makes a Mark in Lymphoma Research

December 8th 2011

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

November 2011: Trials in Progress

December 6th 2011

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

Some Follicular Lymphoma Patients May Benefit From Treatment Delay

December 1st 2011

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.

Dr. Diehl Discusses Brentuximab Vedotin

November 21st 2011

Dr. Volker Diehl from the University of Cologne Discusses Brentuximab Vedotin

Management of Cancer-Related Anemia in 2011

November 21st 2011

Erythropoietin-stimulating agents (ESAs), once considered miracle drugs that enjoyed widespread use for cancer-related anemia, fell into disfavor in 2007.

Refining Maintenance Therapy for Multiple Myeloma

November 21st 2011

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.